ABSTRACT
Sialadenoma papilliferum is a rare tumor, primarily of minor salivary gland origin, first described by Abrams and Finck (Cancer 24:1057-63, 1969). It is both an exophytic and endophytic papillary lesion histologically resembling syringocystadenoma papilliferum of sweat gland. The tumor is considered benign although rare recurrent cases have been reported. Three cases of malignant transformation of sialadenoma papilliferum have been described in the literature. We report a high grade mucoepidermoid carcinoma arising in a background of sialadenoma papilliferum, at the base of the tongue, an unusual location for minor salivary gland neoplasms. Eleven months after excision and nodal dissection, there is no evidence of recurrence or metastasis.
Subject(s)
Carcinoma, Mucoepidermoid/pathology , Neoplasms, Multiple Primary/pathology , Salivary Gland Neoplasms/pathology , Salivary Glands, Minor/pathology , Tongue Neoplasms/pathology , Aged, 80 and over , Carcinoma, Mucoepidermoid/surgery , Diabetes Mellitus , Female , Humans , Hypertension/complications , Neoplasms, Multiple Primary/surgery , Salivary Gland Neoplasms/surgery , Salivary Glands, Minor/surgery , Tongue Neoplasms/surgerySubject(s)
DNA, Mitochondrial/genetics , Liver Failure/genetics , Mitochondrial Diseases/genetics , Mutation , Phosphotransferases (Alcohol Group Acceptor)/genetics , Fatal Outcome , Female , Genotype , Humans , Infant, Newborn , Male , Mitochondrial Diseases/diagnosis , Pedigree , Phenotype , SyndromeABSTRACT
BACKGROUND: Some low-incidence antigens in the Rh blood group system (e.g., VS, Rh32, FPTT) are expressed by more than one Rh complex. We describe a new low-incidence antigen that is present on RBCs with the partial D phenotypes, DIIIa or DOL, on RN RBCs and on one example of STEM+S RBCs. STUDY DESIGN AND METHODS: Standard hemagglutination testing was performed with two sera that agglutinated DIIIa RBCs on our in-house antibody identification panel. DNA-based assays were performed on selected samples. RESULTS: RBCs with the DIIIa (n = 31), DOL (n = 5), or RN (n = 10) phenotype were agglutinated by both sera, as were RBCs from one STEM+S person. Reactivity with RBCs of either DIIIa or DOL phenotypes was stronger than with RN RBCs and could not be separated by adsorption and elution. CONCLUSION: An antibody, anti-DAK, which recognizes a novel low-incidence antigen that is more strongly expressed on DIIIa and DOL RBCs than on RN RBCs is described. The antibody agglutinated RBCs from 4 percent of D+ African American blood donors in New York. The antigen, DAK, has been assigned the ISBT number RH54 (004.054).
